Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Lenalidomide%22&type=Subject&filter%5B%5D=collection%3ACTG
/vufind/Search/Results?lookfor=%22Lenalidomide%22&type=Subject&filter%5B%5D=collection%3ACTG
Search /vufind/Search2/Results?lookfor=%22Lenalidomide%22&type=Subject&filter%5B%5D=collection%3ACTG
PubPharm (86)
1
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) : Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5) : Randomized study with a run-in dose-selection phase to assess the added value of lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score > 4.5)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma - CARTITUDE-4
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma - CARTITUDE-4
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor : A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor : A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma : Multi-center Randomized Study to Compare Efficacy and Safety of Lenalidomide Plus CHOP (L-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
enthalten in:
ClinicalTrials.gov
| 2022
Wird geladen...
8
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma - CARTITUDE-4
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma - CARTITUDE-4
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma - CARTITUDE-4
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
5
6
7
8
9
Nächster »
[9]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
86
Aufsätze
86
E-Artikel
86
E-Ressourcen
Zeitschriftentitel
84
WHO International Clinical Trials Registry Plat...
2
ClinicalTrials.gov
Thema
86
610
86
Study Type: Interventional
62
Phase: Phase 3
46
Recruitment Status: Authorised-recruitment may ...
34
Recruitment Status: Not yet recruiting
28
Medical Condition: Patients with Relapsed Refra...
16
Medical Condition: Relapsed and lenalidomide-re...
16
Phase: Phase 2
6
Medical Condition: Patients with refractory or ...
6
Medical Condition: Patients with relapsed multi...
2
Medical Condition: A Phase III Study Comparing ...
2
Medical Condition: Acute Myeloid Leukemia (AML)...
2
Medical Condition: In this study the bioequival...
2
Medical Condition: MULTIPLE MYELOMA (MM) PATIEN...
2
Medical Condition: Multiple Myeloma resistant o...
2
Medical Condition: Multiple Myeloma resistant o...
2
Medical Condition: Multiple myeloma patients wh...
2
Medical Condition: Patients with Multiple Myelo...
2
Medical Condition: Patients with Relapsed Refra...
2
Medical Condition: Patients with refractory or ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
65
2020-
21
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
84
Englisch
2
Dänisch
Haven't found what you're looking for?
Wird geladen...